The latest update is out from Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc. has revealed encouraging preclinical imaging results for their MNPR-101 therapy, which is linked to a therapeutic radioisotope targeting the uPAR system. This breakthrough could potentially be a significant stride in their therapeutic developments, sparking interest among investors and stakeholders in the biopharmaceutical sector.
For detailed information about MNPR stock, go to TipRanks’ Stock Analysis page.
